Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the onasemnogene abeparvovec phase 1/2a clinical trial

被引：0
|
作者：
Mendell, J. [1 ]
Shell, R. [1 ]
Lehman, K. [1 ]
McColly, M. [1 ]
Lowes, L. [1 ]
Alfano, L. [1 ]
Miller, N. [1 ]
Iammarino, M. [1 ]
Church, K. [1 ]
Ogrinc, F. [2 ]
Ouyang, H. [2 ]
Kernbauer, E. [2 ]
Shah, S. [2 ]
L'Italien, J. [2 ]
Sproule, D. [2 ]
Feltner, D. [2 ]
Al-Zaidy, S. [1 ]
机构：
[1] Nationwide Childrens Hosp, Columbus, OH USA
[2] AveXis Inc, Bannockburn, IL USA
来源：
NEUROMUSCULAR DISORDERS | 2019年 / 29卷
关键词：
D O I：
10.1016/j.nmd.2019.06.513
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.351
引用
收藏
页码：S184 / S184
页数：1
相关论文
共 50 条
  • [31] Intrathecal administration of AVXS-101 gene-replacement therapy (GRT) for spinal muscular atrophy type 2 (SMA2): Phase 1/2A study (strong)
    Finkel, R. S.
    Day, J. W.
    Darras, B. T.
    Kuntz, N. L.
    Connolly, A. M.
    Crawford, T. O.
    Butterfield, R. J.
    Shieh, P. B.
    Tennekoon, G.
    Iannaccone, S. T.
    Meriggioli, M.
    Ogrinc, F. G.
    Kavanagh, S.
    Kernbauer, E.
    Whittle, J.
    L'Italien, J.
    Kaspar, B.
    Sproule, D. M.
    Spector, S. A.
    Feltner, D. E.
    Mendell, J. R.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [32] Intravenous and Intrathecal Onasemnogene Abeparvovec Gene Therapy in Symptomatic and Presymptomatic Spinal Muscular Atrophy: Long-Term Follow-Up Study
    Darras, Basil
    Mercuri, Eugenio
    Strauss, Kevin
    Day, John
    Chien, Yin-Hsiu
    Masson, Ricardo
    Wigderson, Melissa
    Alecu, Iulian
    Ballarini, Nicolas
    Mehl, Lesa
    Marra, Jonathan
    Connolly, Anne
    NEUROLOGY, 2023, 100 (17)
  • [33] Gene Therapy (Onasemnogene Abeparvovec) Is Safe and Effective in Children with Spinal Muscular Atrophy Type 1 on Invasive Long-Term Ventilation
    Narayan, O.
    Alajjuri, M.
    Abusamra, R.
    Mundada, V
    PEDIATRIC PULMONOLOGY, 2023, 58 : S119 - S120
  • [34] Onasemnogene Abeparvovec-xioi Gene-Replacement Therapy in Presymptomatic Spinal Muscular Atrophy: SPR1NT Study Update
    Strauss, Kevin A.
    Farrar, Michelle A.
    Swoboda, Kathryn J.
    Saito, Kayoko
    Chiriboga, Claudia A.
    Finkel, Richard S.
    Iannaccone, Susan T.
    Krueger, Jena M.
    Kwon, Jennifer M.
    McMillan, Hugh J.
    Servais, Laurent
    Mendell, Jerry R.
    Parsons, Julie
    Scoto, Mariacristina
    Shieh, Perry B.
    Zaidman, Craig
    Schultz, Meredith
    Kernbauer, Elaine
    Joshi, Shivani
    Ogrinc, Francis G.
    Kavanagh, Sarah
    Feltner, Douglas E.
    Tauscher-Wisniewski, Sitra
    McGill, Bryan E.
    Sproule, Douglas M.
    Muntoni, Francesco
    NEUROLOGY, 2020, 94 (15)
  • [35] Phase 1 Study of Intrathecal Administration of AVXS-101 Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 2 (SMA2) (STRONG)
    Finkel, Richard S.
    Day, John W.
    Darras, Basil T.
    Kuntz, Nancy L.
    Connolly, Anne M.
    Crawford, Thomas
    Butterfield, Russell J.
    Shieh, Perry B.
    Tennekoon, Gihan
    Iannaccone, Susan T.
    Meriggioli, Matthew
    Spector, Sidney A.
    Ogrinc, Francis G.
    L'Italien, James
    Wells, Courtney
    Kaspar, Brian
    Sproule, Douglas M.
    Feltner, Douglas E.
    Mendell, Jerry R.
    NEUROLOGY, 2019, 92 (15)
  • [36] The Value of AVXS-101 Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 1 (SMA1): Improved Survival, Pulmonary and Nutritional Support, and Motor Function with Decreased Hospitalization
    Dabbous, O.
    Sproule, D.
    Feltner, D.
    Droege, M.
    Khan, F.
    Arjunji, R.
    ANNALS OF NEUROLOGY, 2019, 86 : S133 - S133
  • [37] The value of AVXS-101 gene-replacement therapy (GRT) for spinal muscular atrophy type 1 (SMA1): improved survival, pulmonary and nutritional support, and motor function with decreased hospitalization
    Dabbous, O.
    Sproule, D.
    Feltner, D.
    Droege, M.
    Khan, F.
    Arjunji, R.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S186 - S186
  • [38] Onasemnogene aveparvovec gene therapy for spinal muscular atrophy type 1 (SMA1): Phase 3 study update (STR1VE-EU)
    Mercuri, E.
    Baranello, G.
    Masson, R.
    Boespflug-Tanguy, O.
    Bruno, C.
    Corti, S.
    Daron, A.
    Deconinck, N.
    Scoto, M.
    Servais, L.
    Straub, V.
    Ogrinc, F.
    Ouyang, H.
    Sproule, D.
    Reyna, S.
    Tauscher-Wisniewki, S.
    Baldinetti, F.
    Chand, D.
    Feltner, D.
    Lavrov, A.
    Muntoni, F.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S121 - S121
  • [39] AVXS-101 Gene Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 1 (SMA1): Pivotal Phase 3 Study (STR1VE) Update
    Shell, R.
    Day, J.
    Chiriboga, C.
    Crawford, T. O.
    Darras, B. T.
    Finkel, R.
    Connolly, A. M.
    Iannaccone, S. T.
    Kuntz, N. L.
    Pena, L. D. M.
    Schultz, M.
    Shieh, P. B.
    Smith, E. C.
    Feltner, D. E.
    Ogrinc, F. G.
    Macek, T. A.
    Wells, C.
    Muehring, L. M.
    L'Italien, J.
    Sproule, D. M.
    Kaspar, B. K.
    Mendell, J. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [40] Onasemnogene Abeparvovec-xioi Gene-Replacement Therapy for Spinal Muscular Atrophy Type 1: Pulmonary and Ventilatory Findings from the Pivotal Phase 3 US Study (STR1VE)
    Shell, R.
    Day, J. W.
    Chiriboga, C. A.
    Crawford, T. O.
    Darras, B. T.
    Finkel, R. S.
    Connolly, A. M.
    Iannaconne, S. T.
    Kuntz, N. L.
    Pena, L. D. M.
    Shieh, P. B.
    Smith, E. C.
    Kwon, J. M.
    Zaidman, C.
    Schultz, M.
    Feltner, D. E.
    Tauscher-Wisniewski, S.
    Ogrinc, F. G.
    Thomasma, P.
    Ouyang, H.
    Macek, T. A.
    Kernbauer, E.
    Sproule, D. M.
    Mendell, J. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
12345